Treatment of cancer in dogs and neurodegenerative diseases in humans.|Dr Michael Thurn,Chief Executive Officer,PharmAust Ltd 00:10:00
Michael has over 25 years experience in technical, regulatory, commercial and management roles in research organisations and industry, including early stage, fast growing, private and publicly listed biotechnology companies.In the Biotechnology industry, Michael has held leadership roles at MARP Therapeutics, Botanix Pharmaceuticals (ASX:BOT), Mimetica, Spinifex Pharmaceuticals, Cytopia, Xenome and Novogen. During this time, he has guided a number of New Chemical Entities through discovery, preclinical and clinical development.
